Latest News
Acuity Inc.
- Form S-3ASR Acuity Inc For: 23 October By Investing.com
- Acuity FY 2026: Revenue $4.64B, EPS $17.05— 10-K Summary
- Faricimab Improves Macular Edema and Visual Acuity in Retinal Vein Occlusion: Study
- Claris reports visual acuity gains with experimental LSCD treatment
- Acuity director Laura O’Shaughnessy buys $22,069 in stock By Investing.com
- Bulgaria-active Acuity Analytics acquires US-based Continuus
- Eyestem Reports Visual Acuity Gains In Phase 2 Trial
- Why Acuity Brands (AYI) Stock Is Falling Today
- Acuity Reports FY2026 Revenue $4.64B, Q4 Net Sales $1.24B and Adjusted EPS $5.77
- William Blair downgrades Acuity Brands stock rating on muted lighting market
- HR Acuity secures $47 million minority investment from K1
- Retina Society 2026: MCO-010 optogenetic therapy maintains visual acuity gains through 4 years in advanced RP
Headlines from the last 30 days, linking to the original publishers. See all market news →